| Literature DB >> 30177752 |
Massimo Bonora1, Mariusz R Wieckowski2, David A Sinclair3,4, Guido Kroemer5,6,7,8,9,10,11, Paolo Pinton12,13, Lorenzo Galluzzi14,15,16.
Abstract
A large body of evidence indicates that mitochondrial dysfunction has a major role in the pathogenesis of multiple cardiovascular disorders. Over the past 2 decades, extraordinary efforts have been focused on the development of agents that specifically target mitochondria for the treatment of cardiovascular disease. Despite such an intensive wave of investigation, no drugs specifically conceived to modulate mitochondrial functions are currently available for the clinical management of cardiovascular disease. In this Review, we discuss the therapeutic potential of targeting mitochondria in patients with cardiovascular disease, examine the obstacles that have restrained the development of mitochondria-targeting agents thus far, and identify strategies that might empower the full clinical potential of this approach.Entities:
Mesh：
Substances：
Year: 2019 PMID： 30177752 PMCID： PMC6349394 DOI： 10.1038/s41569-018-0074-0
Source DB: PubMed Journal: Nat Rev Cardiol ISSN： 1759-5002 Impact factor: 32.419